Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy

Onkologie

Volumn 35, Issue 10, 2012, Pages 576-580

  Kaya, Ali O ^a   Coskun, Ugur ^b   Ozkan, Metin ^c   Sevinc, Alper ^d   Yilmaz, Ahmet U ^e   Gumus, Mahmut ^f   Unal, Olcun U ^g   Ozdemir, Nuriye Y ^g   Alici, Suleyman ^h   Berk, Veli ^c   Degerli, Hatice ⁱ   Oner, Mehmet K ^j   Ozturk, Cemil ^b   Kefeli, Umut ^f   Camc, Celalettin ^d  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f Ankara Oncology Training and Research Hospital ^*  (Turkey)

^g ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h MEDICAL PARK HOSPITAL   (Turkey)

ⁱ ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^j DICLE UNIVERSITY   (Turkey)

more..

Author keywords

Advanced urothelial carcinoma; Doxorubicin; Paclitaxel; Second line therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PLATINUM; PREMEDICATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84867246214     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000342674     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8.
3. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg L: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-9.
4. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
5. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
6. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606-7.
7. Kanai K, Kikuchi E, Ohigashi T, Miyajima A, Nakagawa K, Nakashima J, Oya M: Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol 2008;13:510-4.
8. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R; AUO Bladder Cancer Group: Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of Urological Oncology (AUO) trial AB 20/99). Ann Oncol 2011;22:288-94.
9. Rozzi A, Salerno M, Bordin F, De Marco F, Nicola SD, Lanzetta G: Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. Med Oncol 2011;28(suppl 1):426-32.
10. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-40.
11. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606-7.
12. Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M, Culine S: Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy A GETUG phase II study. Clin Genitourin Cancer 2009;7:E28-33.
13. Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr: Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998;16:191-5.
14. Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirrito ML, Sambataro D, Fallica G: Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999;150:11-5.
15. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ Sr: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589-93.
16. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15: 1853-7.
17. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24: 3451-7.
18. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G; Eastern Cooperative Oncology Group: Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007;110:759-63.
19. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5.
20. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-61.